Price
$0.94
Decreased by -2.59%
Dollar Volume (20D)
98.79 K
ADR%
7.5
Earnings Report Date (estimate)
Nov 6, 23 (-0.26)
Market Cap.
49.46 M
Shares Float
51.42 M
Shares Outstanding
52.61 M
Beta
0.74
Price / Earnings
-0.60
BPR
0.57
20D Range
0.85 1.05
50D Range
0.85 1.17
200D Range
0.77 1.78
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Aug 9, 23 0.32
Increased by +162.75%
0.29
Increased by +10.34%
May 4, 23 -0.37
Increased by +22.92%
-0.37
Mar 22, 23 -0.46
Decreased by -21.05%
-0.45
Decreased by -2.22%
Nov 8, 22 -0.48
Decreased by -17.07%
-0.47
Decreased by -2.13%
Aug 9, 22 -0.51
Increased by +7.27%
-0.47
Decreased by -8.51%
May 12, 22 -0.48
Increased by +30.43%
-0.47
Decreased by -2.13%
Mar 10, 22 -0.38
Increased by +60.42%
-0.48
Increased by +20.83%
Nov 4, 21 -0.41
Decreased by -355.56%
-0.56
Increased by +26.79%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jun 30, 23 0.00
Decreased by N/A%
-16.90 M
Increased by +30.61%
Decreased by N/A%
Decreased by N/A%
Mar 31, 23 0.00
Decreased by N/A%
-18.34 M
Increased by +20.33%
Decreased by N/A%
Decreased by N/A%
Dec 31, 22 0.00
Decreased by N/A%
-21.63 M
Increased by +64.11%
Decreased by N/A%
Decreased by N/A%
Sep 30, 22 0.00
Decreased by -100.00%
-22.89 M
Decreased by -21.73%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-24.35 M
Decreased by -3.20%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-23.02 M
Increased by +15.37%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by -100.00%
-60.26 M
Decreased by -52.87%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 6.25 M
Decreased by -81.93%
-18.80 M
Decreased by -461.45%
Decreased by -300.66%
Decreased by -3.01 K%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.